NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Azithromycin not effective against COVID-19, trial confirms

Azithromycin not effective against COVID-19, trial confirms

26 April 2021 · Listed under COVID-19, Respiratory

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Image: Doctur4U

The ATOMIC2 trial, which was supported by the NIHR Oxford Biomedical Research Centre (BRC), was established to investigate if a common antibiotic called azithromycin could prevent patients with mild-moderate COVID-19 from getting worse.

Azithromycin is a safe, inexpensive and commonly prescribed antibiotic that is available worldwide. It has a wide range of antibacterial, anti-inflammatory and antiviral properties, but there were no strong data proving whether it was effective in COVID-19.

In the last few months, several trials have reported their results. Four trials have assessed the treatment in nearly 9,000 hospitalised patients and found no benefit from azithromycin in reducing the number of deaths or how long people stay in hospital.

However it was important also to determine if azithromycin might be effective if given earlier in the disease before people became severely unwell.

In the ATOMIC2 trial, 298 participants were randomised to either azithromycin (500 mg once daily for 14 days) or to standard treatment without azithromycin. The primary endpoint – death or hospitalisation from any cause – was not significantly different between the two groups; neither were rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events.

The findings were posted on SSRN/Preprints with The Lancet. Additional details and analyses on azithromycin from the ATOMIC2 trial will be shared in the near future in peer-reviewed journals.

This study adds to the body of evidence from severe disease, and to the recent results of the larger PRINCIPLE trial, also from Oxford University, which looked at a short, three-day course of azithromycin in mild, early disease in people treated at home. Each of these studies has found no evidence of a benefit from azithromycin therapy.

Therefore in people with COVID-19, whether in mild early disease; in people with moderate disease studied in ATOMIC2; or in people hospitalised with severe disease, azithromycin has no clinical benefit.

Dr Timothy Hinks (left), Chief Investigator of the ATOMIC2 trial and an Oxford BRC Senior Research Fellow, said: “Azithromycin is a very valuable antibiotic used the world over for treating a wide range of serious infections, and remains an essential tool for any healthcare system. Its overuse, where not clearly proven to be of benefit, carries a very strong risk of driving the development of multi-resistant bacteria.

“The ATOMIC2 trial adds to the now very strong set of evidence that azithromycin is not effective in COVID-19 and it is essential it should be preserved for diseases where it is really needed.”

The ATOMIC2 trial was conducted by the Oxford Clinical Trials Research Unit and the University of Oxford’s Nuffield Department of Medicine. As well as the Oxford BRC, the trial was supported by Pfizer and from philanthropic donations provided via the University of Oxford COVID-19 Research Response Fund.

← National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines
Study highlights role of BMI in increased COVID-19 risks →

News

  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
  • Oxford’s medical, health and life sciences research excellence recognised 12 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre